3 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Recurrent Solid Tumors: new trials by email Literature Review of Recurrent Solid Tumors trials Research Report on Recurrent Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors ZEN003694, Niraparib - Ovarian Cancer, Recurrent Solid Tumors | Phase 1 | Withdrawn | Haider Mahdi | 2024-01-23 | 2024-10-15 | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors RO7566802, Atezolizumab - Locally Advanced Solid Tumors, Recurrent Solid Tumors | Phase 1 | Active not recruiting | Genentech, Inc. | 65 | 2023-11-27 | 2026-07-28 |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) IMA201 Product, IMADetect® - Solid Tumor, Cancer | Phase 1 | Completed | Immatics US, Inc. | 7 | 2018-12-19 | 2025-02-04 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer IT-141 - Cancer, Neoplasms | Phase 1 | Terminated | Intezyne Technologies, Inc. | 10 | 2017-03-23 | 2020-12-22 |
| ONO-4538 Phase I Study in Patients With Solid Tumor ONO-4538 - Advanced Solid Tumors, Recurrent Solid Tumors | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 18 | 2014-10-01 | 2024-05-03 |
| ONO-4538 Phase I Study in Patients With Solid Tumor ONO-4538 - Advanced Solid Tumors, Recurrent Solid Tumors | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 18 | 2014-10-01 | 2024-05-06 |
Neoplasms (2) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Nivolumab (2) · Irinotecan (1) · atezolizumab (1) · niraparib (1)
Ono Pharmaceutical Co., Ltd. (2) · Genentech, Inc. (1) · Haider Mahdi (1) · Immatics US, Inc. (1) · Intezyne Technologies, Inc. (1)
United States (4) · South Korea (2) · Australia (1) · Canada (1) · Germany (1) · Singapore (1) · United Kingdom (1)
Mitsunobu Tanimoto (2) · Cedrik Britten, MD, PhD (1) · Haider S Mahdi, MD (1) · Kit Wong, MD (1) · Minal Barve, MD (1)
2023 (1)